Pacific Edge CEO Dr Peter Meintjes talked with Proactive at the ASX Small and Mid-Cap Conference about the progress of its APAC operations, Cxbladder tests and the milestones it hopes to achieve in the coming months. Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. Cxbladder is a suite of non-invasive genomic urine tests optimised for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritising time and clinical resources to optimise practice workflow and improve efficiency. Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. #PacificEdgeLimited #ProactiveInvestors #PeterMeintjes #CancerDiagnostics #BladderCancer